Erythema multiforme-like rash upon antimelanoma therapy with BRAF and MEK inhibitors

被引：0
作者：
Graen, Franziska [1 ]
Goebeler, Matthias [1 ]
Gesierich, Anja [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Dermatol Venereol & Allergol, Wurzburg, Germany
来源：
EUROPEAN JOURNAL OF DERMATOLOGY | 2019年 / 29卷 / 01期
关键词：
TRAMETINIB; DABRAFENIB; MELANOMA; PHASE-3;
D O I：
10.1684/ejd.2019.3511
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：107 / 108
页数：3
相关论文
共 6 条
  • [1] Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
    Dummer, Reinhard
    Ascierto, Paolo A.
    Gogas, Helen J.
    Arance, Ana
    Mandala, Mario
    Liszkay, Gabriella
    Garbe, Claus
    Schadendorf, Dirk
    Krajsova, Ivana
    Gutzmer, Ralf
    Sileni, Vanna Chiarion
    Dutriaux, Caroline
    de Groot, Jan Willem B.
    Yamazaki, Naoya
    Loquai, Carmen
    Moutouh-de Parseval, Laure A.
    Pickard, Michael D.
    Sandor, Victor
    Roberti, Caroline
    Flaherty, Keith T.
    [J]. LANCET ONCOLOGY, 2018, 19 (10) : 1315 - 1327
  • [2] Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
    Grob, Jean Jacques
    Amonkar, Mayur M.
    Karaszewska, Boguslawa
    Schachter, Jacob
    Dummer, Reinhard
    Mackiewicz, Andrzej
    Stroyakovskiy, Daniil
    Drucis, Kamil
    Grange, Florent
    Chiarion-Sileni, Vanna
    Rutkowski, Piotr
    Lichinitser, Mikhail
    Levchenko, Evgeny
    Wolter, Pascal
    Hauschild, Axel
    Long, Georgina V.
    Nathan, Paul
    Ribas, Antoni
    Flaherty, Keith
    Sun, Peng
    Legos, Jeffrey J.
    McDowell, Diane Opatt
    Mookerjee, Bijoyesh
    Schadendorf, Dirk
    Robert, Caroline
    [J]. LANCET ONCOLOGY, 2015, 16 (13) : 1389 - 1398
  • [3] Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors
    Gutzmer, R.
    Hassel, J. C.
    Kaehler, K. C.
    Loquai, C.
    Moessner, R.
    Ugurel, S.
    Zimmer, L.
    [J]. HAUTARZT, 2014, 65 (07): : 582 - +
  • [4] Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
    Lacouture, Mario E.
    Duvic, Madeleine
    Hauschild, Axel
    Prieto, Victor G.
    Robert, Caroline
    Schadendorf, Dirk
    Kim, Caroline C.
    McCormack, Christopher J.
    Myskowski, Patricia L.
    Spleiss, Olivia
    Trunzer, Kerstin
    Su, Fei
    Nelson, Betty
    Nolop, Keith B.
    Grippo, Joseph F.
    Lee, Richard J.
    Klimek, Matthew J.
    Troy, James L.
    Joe, Andrew K.
    [J]. ONCOLOGIST, 2013, 18 (03) : 314 - 322
  • [5] Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
    Long, Georgina V.
    Stroyakovskiy, Daniil
    Gogas, Helen
    Levchenko, Evgeny
    de Braud, Filippo
    Larkin, James
    Garbe, Claus
    Jouary, Thomas
    Hauschild, Axel
    Grob, Jean-Jacques
    Chiarion-Sileni, Vanna
    Lebbe, Celeste
    Mandala, Mario
    Millward, Michael
    Arance, Ana
    Bondarenko, Igor
    Haanen, John B. A. G.
    Hansson, Johan
    Utikal, Jochen
    Ferraresi, Virginia
    Kovalenko, Nadezhda
    Mohr, Peter
    Probachai, Volodymr
    Schadendorf, Dirk
    Nathan, Paul
    Robert, Caroline
    Ribas, Antoni
    DeMarini, Douglas J.
    Irani, Jhangir G.
    Swann, Suzanne
    Legos, Jeffrey J.
    Jin, Fan
    Mookerjee, Bijoyesh
    Flaherty, Keith
    [J]. LANCET, 2015, 386 (9992) : 444 - 451
  • [6] Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
    Welsh, Sarah J.
    Corrie, Pippa G.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (02) : 122 - 136
1